Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials.

中文翻译：

---

早期乳腺癌新辅助化疗与辅助化疗的长期结果：来自十项随机试验的个体患者数据的荟萃分析。

早期乳腺癌的新辅助化疗 (NACT) 可以使保乳手术更加可行，并且可能比手术后给予相同的化疗更有可能根除微转移性疾病。我们通过对来自相关随机试验的个体患者数据进行协作荟萃分析，调查了 NACT 的长期益处和风险以及肿瘤特征对结果的影响。